Shilpa Medicare’s Bengaluru Unit VI receives USFDA EIR with VAI classification, validating its complex dosage manufacturing facility.

• The facility handles oral dissolving films and transdermal systems; a USFDA inspection was held in October 2024.
• Already approved by EMA, MHRA, SFDA, and TGA; supplies oral films to the US, and transdermal films in Europe.
• Certification supports global market expansion and enhances regulatory credibility across key pharmaceutical markets.